Xavier Forns

Cap de la Unitat

Grup de recerca

Malalties hepàtiques víriques, genètiques i immuno-mediades Group leader (R4)

xforns@clinic.cat 0000-0002-8188-1764

Publicacions destacades

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules

Autors:
Marino, Zoe; Darne, Anna; Lens, Sabela; Sapena, Victor; Diaz, Alba;

(...)

Ayuso, Carmen; Rios, Jose; Forns, Xavier; Bruix, Jordi; Reig, Maria.

Referència: Journal Of Hepatology 2019.
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.

Autors:
Perpinan, Elena; Caro-Perez, Noelia; Garcia-Gonzalez, Neris; Gregori, Josep; Gonzalez, Patricia;

(...)

Koutsoudakis, George; Quer, Josep; Gonzalez-Candelas, Fernando; Forns, Xavier; Perez-del-Pulgar, Sofia.

Referència: Journal Of Viral Hepatitis 2018.
Shorter HBIG administration is not associated to HBV recurrence when receiving combined prophylaxis after liver transplantation.

Autors:
Lens S; García-Eliz M; Fernández I; Castells L; Bonacci M;

Mas A; Crespo G; Buti M; Prieto M; Forns X .

Referència: Liver International 2018.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Autors:
Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K;

(...)

Shulman NS; Liu W; Samanta S; Trinh R; Forns X .

Referència: Hepatology 2018.
Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.

Autors:
Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B;

(...)

Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X .

Referència: Journal Of Hepatology 2018.
Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.

Autors:
Bonacci, Martin; Lens, Sabela; Marino, Zoe; Londono, Maria-Carlota; Rodriguez-Tajes, Sergio;

Sanchez-Tapias, Jose M; Ramos-Casals, Manel; Hernandez-Rodriguez, Jose; Forns, Xavier.

Referència: Gastroenterology 2018.
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition

Autors:
Crespo, Gonzalo; Trota, Nuria; Londono, Maria-Carlota; Mauro, Ezequiel; Baliellas, Carme;

Castells, Lluis; Castellote, Jose; Tort, Jaume; Forns, Xavier; Navasa, Miquel.

Referència: Journal Of Hepatology 2018.
Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.

Autors:
Lens, Sabela; Alvarado-Tapias, Edilmar; Marino, Zoe; Londono, Maria-Carlota; Llop, Elba;

(...)

Hernandez-Gea, Virginia; Bosch, Jaume; Villanueva, Candid; Forns, Xavier; Carlos Garcia-Pagan, Juan.

Referència: Gastroenterology 2017.
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Autors:
Forns X; Lee SS; Valdes J; Lens S; Ghalib R;

(...)

Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ .

Referència: Lancet Infectious Diseases 2017.
EASL Recommendations on Treatment of Hepatitis C 2016

Autors:
;European Ass Study Liver;

Referència: Journal Of Hepatology 2017.

Projectes destacats

Estudio de la disfunción de la respuesta inmune adaptativa periférica e intrahepática en las diferentes fases de la hepatitis crónica por el virus de la hepatitis B

Investigador/a principal: Xavier Forns Bernhardt

Finançador: Instituto de Salud Carlos III

Codi: PI18/00079

Durada: 01/01/2019 - 01/01/2022
Evaluación prospectiva de un modelo externalizado de consulta especializada con intervención educacional para reducir la reinfección por el virus de la hepatitis C en un centro de reducción de daños

Investigador/a principal: Xavier Forns Bernhardt

Finançador: Ministerio de Sanidad

Codi: 2020I018

Durada: 01/01/2021 - 31/12/2022
TherVacB: A therapeutic vaccine to cure hepatitis B

Investigador/a principal: Xavier Forns Bernhardt

Finançador: European Commission

Codi: 848223

Durada: 01/01/2020 - 31/12/2024

Web: https://www.thervacb.eu/
Defining the best strategy for global HCV screening, linkage-to-care, education and prevention in PWID population and validation of a new diagnostic dried blood spot test

Investigador/a principal: Sabela Lens García

Finançador: GILEAD SCIENCES INC

Codi: IN-ES-987-5349

Durada: 02/05/2018 - 31/03/2022

Xavier Forns

Grup de recerca

Publicacions destacades

Projectes destacats

Estudio de la disfunción de la respuesta inmune adaptativa periférica e intrahepática en las diferentes fases de la hepatitis crónica por el virus de la hepatitis B

Evaluación prospectiva de un modelo externalizado de consulta especializada con intervención educacional para reducir la reinfección por el virus de la hepatitis C en un centro de reducción de daños

TherVacB: A therapeutic vaccine to cure hepatitis B

Defining the best strategy for global HCV screening, linkage-to-care, education and prevention in PWID population and validation of a new diagnostic dried blood spot test

Subscriu-te a la Newsletter del Clínic